Founded in 2017 and headquartered in Paris, France, Alderaan Biotechnology works with world-class teams in the fields of immunomodulation and immunotherapy of cancer focusing on the development of monoclonal antibodies with technologies aiming at Treg depletion in solid tumours.
The company raised €1.5M ($1.7M) in 2017 from co-founder AdBio partners and €18.5M ($20.7M) in 2019 from AdBio partners and Medicxi.
Alderaan Biotechnology works in partnership with the French national Institute for health and medical research (INSERM) and with the Institut Paoli Calmettes, Marseille, France.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Paris
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- alderaan-biotechnology.com
- HQ
- PARIS
Alderaan Biotechnology Questions
Alderaan Biotechnology's website is alderaan-biotechnology.com
Alderaan Biotechnology's LinkedIn profile is https://fr.linkedin.com/company/alderaan-biotechnology
Alderaan Biotechnology has
3 employees.
View email and phone details for 3
employees at Alderaan Biotechnology.
Alderaan Biotechnology's industry is
Biotechnology Research
Alderaan Biotechnology's top competitors are
Bioaster,
Htl Biotechnology,
Abivax,
Ags Therapeutics,
Neoventures Biotechnology Europe,
Whitelab Genomics,
Everzom,
Aqemia,
Acticor Biotech,
Diaorigin Biotechnology.
Alderaan Biotechnology's categories are Biotechnology Research
Alderaan Biotechnology's founding year is 2017
